« Back
Home /
Infigratinib phosphate

Infigratinib phosphate

Item no.	HY-13311A-25mg
Manufacturer	MedChem Express
CASRN	1310746-10-1
Amount	25 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 mg 25 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.59
Citations	[1]Guagnano V, et al. Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-me thyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor T\|[2]Konecny GE, et al. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells. Mol Cancer Ther. 2013 May;12(5):632-42. bioRxiv. 2025 Nov 14. Ann Rheum Dis. 2016 May;75(5):883-90. Anti-Cancer Drug. 2022 Dec. Biochim Biophys Acta Mol Basis Dis. 2025 May 29:167940. Biomed Pharmacother. 2025 Oct 21:192:118677. Biomedicines. 2023 Nov 27;11(12):3155. bioRxiv. 2024 May 14. bioRxiv. 2025 Jun 16:2025.06.11.659120. Biotechnol J. 2024 Aug;19(8):e2400278. Cancer Discov. 2018 Mar;8(3):354-369. Cancer Discov. 2019 Dec;9(12):1686-1695. Cancers (Basel). 2024 Jul 3;16(13):2447. Cell Death Dis. 2025 Jul 2;16(1):485. Cell Rep. 2024 Dec 30;44(1):115116. Cell Rep. 2019 Feb 12;26(7):1709-1717.e3. Chem Res Toxicol. 2021 Jul 19;34(7):1800-1813. Department Biologie. Friedrich-Alexander University Erlangen-Nuremberg. March.10th.2016. Development. 2025 May 15;152(10):dev204687. FEBS Open Bio. 2023 May;13(5):804-817. Heliyon. 2024 May 10. J Control Release. 2018 Sep 28;286:254-263. J Exp Clin Cancer Res. 2021 Aug 27;40(1):273. J Med Chem. 2025 Mar 13;68(5):5907-5925. J Neuroinflammation. 2023 Jan 17;20(1):10. medRxiv. 2023 Mar 17. Nat Commun. 2022 Aug 4;13(1):4534. Nature. 2022 Aug;608(7923):609-617. NPJ Precis Oncol. 2021 Jul 16;5(1):66. Obesity (Silver Spring). 2019 Mar;27(3):399-408. Oncogene. 2016 Apr 28;35(17):2247-65. Oncotarget. 2020 Nov 3;11(44):3921-3932. Patent. US20220175722A1. Pharmaceutics. 2025 Oct 31;17(11):1415. Res Sq. 2025 Jul 24. RSC Adv. 2020,10, 16231-16244. Sci Rep. 2016 Apr 28;6:25272. Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. Signal Transduct Target Ther. 2025 Nov 3;10(1):360. Signal Transduct Target Ther. 2025 Nov 4;10(1):361. The 22nd National Graduate Research Conference. 2021 Mar 25. Thorac Cancer. 2025 Jan;16(1):e15488. Tissue Eng Part A. 2019 Mar;25(5-6):437-445. University of Auckland. 2025. World J Exp Med. 2025 Jun 20;15(2):100443.
Smiles	O=P(O)(O)O.ClC1=C(C(Cl)=C(C=C1OC)OC)NC(N(C2=CC(NC3=CC=C(C=C3)N4CCN(CC4)CC)=NC=N2)C)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	BGJ-398 phosphate,NVP-BGJ398 (phosphate)
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Category	Reference compound / Active compounds; API
Manufacturer - Targets	FGFR
Manufacturer - HS Code	H302, H315, H319
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	658.47
Product Description	Infigratinib phosphate (BGJ-398 phosphate; NVP-BGJ398 phosphate) is a potent inhibitor of the FGFR family with IC50 of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.
Manufacturer - Research Area	Cancer
Solubility	DMSO : 8.75 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	Protein Tyrosine Kinase/RTK
Clinical information	Launched
Isoform	FGFR1; FGFR2; FGFR3; FGFR4
UNSPSC Code	12352005
Precautionary	H302, H315, H319

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.